Guy-Anne Turgeon1, Luis Souhami2, Fabio L Cury1, Sergio L Faria1, Marie Duclos1, Jeremy Sturgeon3, Wassim Kassouf4. 1. Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada. 2. Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: luis.souhami@muhc.mcgill.ca. 3. Department of Medical Oncology, McGill University Health Centre, Montreal, Quebec, Canada. 4. Department of Urology, McGill University Health Centre, Montreal, Quebec, Canada.
Abstract
PURPOSE/OBJECTIVE(S): To review our experience with bladder-preserving trimodality treatment (TMT) using hypofractionated intensity modulated radiation therapy (IMRT) for the treatment of elderly patients with muscle-invasive bladder cancer. METHODS AND MATERIALS: Retrospective study of elderly patients treated with TMT using hypofractionated IMRT (50 Gy in 20 fractions) with concomitant weekly radiosensitizing chemotherapy. Eligibility criteria were as follows: age ≥70 years, a proven diagnosis of muscle-invasive transitional cell bladder carcinoma, stage T2-T3N0M0 disease, and receipt of TMT with curative intent. Response rate was assessed by cystoscopic evaluation and bladder biopsy. RESULTS: 24 patients with a median age of 79 years were eligible. A complete response was confirmed in 83% of the patients. Of the remaining patients, 1 of them underwent salvage cystectomy, and no disease was found in the bladder on histopathologic assessment. After a median follow-up time of 28 months, of the patients with a complete response, 2 patients had muscle-invasive recurrence, 1 experienced locoregional failure, and 3 experienced distant metastasis. The overall and cancer-specific survival rates at 3 years were 61% and 71%, respectively. Of the surviving patients, 75% have a disease-free and functioning bladder. All patients completed hypofractionated IMRT, and 19 patients tolerated all 4 cycles of chemotherapy. Acute grade 3 gastrointestinal or genitourinary toxicities occurred in only 4% of the patients, and acute grade 3 or 4 hematologic toxicities, liver toxicities, or both were experienced by 17% of the cohort. No patient experienced grade 4 gastrointestinal or genitourinary toxicity. CONCLUSIONS: Hypofractionated IMRT with concurrent radiosensitizing chemotherapy appears to be an effective and well-tolerated curative treatment strategy in the elderly population and should be considered for patients who are not candidates for cystectomy or who wish to avoid cystectomy.
PURPOSE/OBJECTIVE(S): To review our experience with bladder-preserving trimodality treatment (TMT) using hypofractionated intensity modulated radiation therapy (IMRT) for the treatment of elderly patients with muscle-invasive bladder cancer. METHODS AND MATERIALS: Retrospective study of elderly patients treated with TMT using hypofractionated IMRT (50 Gy in 20 fractions) with concomitant weekly radiosensitizing chemotherapy. Eligibility criteria were as follows: age ≥70 years, a proven diagnosis of muscle-invasive transitional cell bladder carcinoma, stage T2-T3N0M0 disease, and receipt of TMT with curative intent. Response rate was assessed by cystoscopic evaluation and bladder biopsy. RESULTS: 24 patients with a median age of 79 years were eligible. A complete response was confirmed in 83% of the patients. Of the remaining patients, 1 of them underwent salvage cystectomy, and no disease was found in the bladder on histopathologic assessment. After a median follow-up time of 28 months, of the patients with a complete response, 2 patients had muscle-invasive recurrence, 1 experienced locoregional failure, and 3 experienced distant metastasis. The overall and cancer-specific survival rates at 3 years were 61% and 71%, respectively. Of the surviving patients, 75% have a disease-free and functioning bladder. All patients completed hypofractionated IMRT, and 19 patients tolerated all 4 cycles of chemotherapy. Acute grade 3 gastrointestinal or genitourinary toxicities occurred in only 4% of the patients, and acute grade 3 or 4 hematologic toxicities, liver toxicities, or both were experienced by 17% of the cohort. No patient experienced grade 4 gastrointestinal or genitourinary toxicity. CONCLUSIONS: Hypofractionated IMRT with concurrent radiosensitizing chemotherapy appears to be an effective and well-tolerated curative treatment strategy in the elderly population and should be considered for patients who are not candidates for cystectomy or who wish to avoid cystectomy.
Authors: John J Coen; Peixin Zhang; Philip J Saylor; Cheryl T Lee; Chin-Lee Wu; William Parker; Timothy Lautenschlaeger; Anthony L Zietman; Jason A Efstathiou; Ashesh B Jani; Omer Kucuk; Luis Souhami; Joseph P Rodgers; Howard M Sandler; William U Shipley Journal: J Clin Oncol Date: 2018-11-15 Impact factor: 44.544
Authors: Anne Kaufmann; Heike Schmidt; Christian Ostheimer; Janine Ullrich; Margarete Landenberger; Dirk Vordermark Journal: Support Care Cancer Date: 2014-12-06 Impact factor: 3.603
Authors: M Bonet; T Bonfill; M Nuñez; L De Verdonces; E Mur; E Gallardo; L Fernandez-Morales; A Aguilar; J Prats; M Arenas Journal: Clin Transl Oncol Date: 2017-11-20 Impact factor: 3.405